Harrow Secures Medicare Part D Market Access for Vevye

Harrow announced that beginning January 1, 2025, Harrow’s dry eye disease treatment, Vevye, will be included in the formularies of major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors provide coverage for more than 25 million Medicare Part D beneficiaries.

Beyond Medicare Part D coverage, Vevye has also secured broad insurance access across various other programs. It is now covered by 100% of US Medicaid programs and approximately 60% of commercial insurance plans, according to Harrow. 

“Medicare access is essential for Vevye's continued successful progression as a preferred dry eye disease prescription choice, and we’re thrilled that we’ve secured these initial Medicare Part D formulary coverages—including with some of the largest 2025 Medicare Part D payers,” Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said in a company news release. “For too long, Medicare beneficiaries have lacked an accessible, effective, and highly tolerable dry eye treatment. With 67 million Medicare beneficiaries in the US, including the 54 million with Medicare Part D prescription coverage, there is a substantial need for the unique clinical benefits that Vevye offers."

“Seniors face an increased risk for this chronic condition, affecting their comfort, vision, and overall quality of life. With this expanded access, we can better serve Medicare beneficiaries by improving their eye health, independence, and quality of life," Mr. Baum added.